Ten years survival of FIGO Stage IIIC epithelial ovarian cancer cases due to lymph node metastases only

Purpose of investigation: In this paper the authors have analyzed the long-term survival of women with Stage Ill ovarian cancer due to lymph node metastasis. Materials and Methods: This retrospective study included 27 patients with FIGO Stage IIIC epithelial ovarian carcinoma due to lymph node metastases observed consecutively at the Mangiagalli Clinic of Milan from 1982 to 2008. Results: Two cases had Fallopian tube carcinoma. A total of ten recurrences were observed. Median time to recurrence was 158 months. The five-year disease-free survival (DFS) was 57.7%. The ten-year corresponding value was 53.2%. Median survival time was 158 months, with median follow-up time of 169 months. The five-year (overall survival) OS rate was 77.1%; the ten-year rate was 55.4%. Conclusion: Women with ovarian cancer Stage IIIC due to nodal involvement have a five-year OS of about 80% and a ten-year OS of about 50%.

Ovarian cancer; Survival; Node metastases

[1] Onda T., Yoshikawa H., Yasugi T., Mishima M., Nakagawa S., Yamada M. et al.: “Patients with ovarian carcinoma upstaged to Stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients”. Cancer, 1998, 83, 1555.

[2] Kanazawa K., Suzuki T., Tokashiki M.: “The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival”. Gynecol. Oncol., 1999, 73, 237.

[3] Cliby W.A., Aletti G.D., Wilson T.O., Podratz K.C.: “Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?”. Gynecol. Oncol., 2006, 103, 797.

[4] Baek S.J., Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T. et al.: “Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of Stage IIIC epithelial ovarian cancer”. J. Gynecol. Oncol., 2008, 19, 223.

[5] Herzog T.J.: “Assessing the adequacy of surgical staging for ovarian cancer”. Gynecol. Oncol., 2006, 103, 781.

[6] Ferrandina G., Scambia G., Legge F., Petrillo M., Salutari V.: “Ovarian cancer patients with “node-positive-only” Stage IIIC disease have a more favorable outcome than Stage IIIA/B”. Gynecol. Oncol., 2007, 107, 154.

[7] Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V. et al.: “Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples”. Br. J. Cancer, 1977, 35, 1.